Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Jörg Trojan, Oliver Waidmann Medizinische Klinik 1, Universitätsklinikum Frankfurt, Germany Abstract: Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). In recent years, several investigational agents m...

Full description

Bibliographic Details
Main Authors: Trojan J, Waidmann O
Format: Article
Language:English
Published: Dove Medical Press 2016-09-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
Hepatocellular carcinoma
receptor tyrosine kinase inhibitor
sorafenib
regorafenib
lenvatinib
tivantinib
cabozantinib
ramucirumab
immunotherapy
anti-CTLA-4
anti-PD1
oncolytic virus.
Online Access:https://www.dovepress.com/role-of-regorafenib-as-second-line-therapy-and-landscape-of-investigat-peer-reviewed-article-JHC

Internet

https://www.dovepress.com/role-of-regorafenib-as-second-line-therapy-and-landscape-of-investigat-peer-reviewed-article-JHC

Similar Items